{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261799","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.472428+00:00","generated_at":"2026-05-17T00:55:31.646964+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cullinan reports Phase 1 CLN-049 data: 31% CRc at 12 μg/kg in r/r AML","bullets":["Anti-leukemic activity at doses ≥6 μg/kg: CRc 30%, ORR 57% (n=23); at 12 μg/kg CRc 31%, ORR 69% (n=13).","Responses across genetic risk; in TP53-mutated AML 4/5 patients responded (2 CRh, 2 MLFS) at 12 μg/kg.","Safety manageable: all CRS Grade 1-2; no discontinuations due to CRS or ICANS. Common TEAEs: CRS 40%, IRR 35%.","Oral presentation at ASH on Dec 8, 2025; dose escalation ongoing. Company to host investor event Dec 8."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261799","json":"https://secwatch.observer/filing/0001193125-25-261799.json","markdown":"https://secwatch.observer/filing/0001193125-25-261799.md","text":"https://secwatch.observer/filing/0001193125-25-261799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312525261799/0001193125-25-261799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312525261799/cgem-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:55:31.646964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}